This is really interesting. As I was reading the article I was wondering how they were going to wring money out of it, as amlodipine is off patent. Then I got to this part:
“While amlodipine shows promise in preclinical models, it is not currently suitable for use in ADHD in its marketed form,” Karlsson noted. “Further optimization through chemical modification is necessary to enhance CNS selectivity and ensure a favorable therapeutic index in the context of ADHD.”
Classic big pharma. Slightly tweak an existing drug in an insignificant way so that you can get a new patent on it and charge exorbitant prices.
They’re reformulate it and call it something new. They’ll still sell amlodipine for blood pressure.